Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Mar 5;136(5):607-609.
doi: 10.1097/CM9.0000000000002604.

A multi-center randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients

Xiang Zheng  1 , Weijie Zhang  2 , Hua Zhou  3 , Ronghua Cao  4 , Zhangfei Shou  5 , Shuwei Zhang  6 , Ying Cheng  7 , Xuchun Chen  7 , Chenguang Ding  8 , Ning Li  3 , Shaohua Shi  3 , Qiang Zhou  9 , Qiuyuan Chen  4 , Gang Chen  4 , Zheng Chen  10 , Peijun Zhou  11 , Xiaopeng Hu  1 , Wujun Xue  8 , Xiaodong Zhang  1 , Ning Na  12 , Wei Wang  1
Affiliations
Randomized Controlled Trial

A multi-center randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients

Xiang Zheng et al. Chin Med J (Engl). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of renal function between rCNI + SRL treatment group and sCNI + MPA treatment group: (A) Changes in eGFR by treatment regimens, (B) Changes in BUN by treatment regimens, and (C) Changes in sCr by treatment regimens. ∗P < 0.05. BUN: Blood urea nitrogen; rCNI + SRL: Reduced calcineurin inhibitor + sirolimus; sCNI + MPA: Standard calcineurin inhibitor + mycophenolic acid; sCr: Serum creatinine; eGFR: Estimated glomerular filtration rate.
See this image and copyright information in PMC

References

    1. Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs 2020; 44:140–152. doi: 10.1111/aor.13551. - PubMed
    1. Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009; 87:S1–S6. doi: 10.1097/TP.0b013e3181a059a1. - PubMed
    1. Zheng X, Zhang W, Zhou H, Cao R, Shou Z, Zhang S, et al. . A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients. Chin Med J 2022; 135:1597–1603. doi: 10.1097/CM9.0000000000001866. - PMC - PubMed
    1. Saliba F, Fischer L, de Simone P, Bernhardt P, Bader G, Fung J. Association between renal dysfunction and major adverse cardiac events after liver transplantation: evidence from an international randomized trial of everolimus-based immunosuppression. Ann Transplant 2018; 23:751–757. doi: 10.12659/AOT.911030. - PMC - PubMed

Publication types